glp-1 obesity drugs pipeline Transforming obesity: The advancement of multi-receptor drugs: Cell GLP-1 Pipeline graphic : r/Zepbound
Description
Exclusion criteria: Non-RCTs (cohort, casecontrol, cross-sectional studies, case reports)
88 , 89 Common reasons include gastrointestinal side effects, injection burden, high cost, and limited insurance coverage
Lancet 2018;391:260718.ArticlePubMed 46
Epidemiological evidence demonstrates a strong association between obesity and KOA, highlighting shared pathogenic mechanisms
Accordingly, dulaglutide, liraglutide and semaglutide are indicated to reduce cardiovascular risk in people with type 2 diabetes
